Simple Summary Classic Hodgkin lymphoma (cHL) has a high cure rate with chemotherapy,
but 10–30% of patients experience relapse or refractory (R/R) disease, depending on stage …

Background Edible and medicinal herbs 1 (EMHs) refer to a class of substances with dual
attribution of food and medicine. These substances are traditionally used as food and also …

In recent years, cancer immunotherapy research has made remarkable progress, completely
transforming the cancer treatment landscape. In 2021, we proudly introduced the Special …

BACKGROUND Inhibition of Bruton's tyrosine kinase with ibrutinib blocks the function of
myeloid-derived suppressor cells (MDSC). The combination of ibrutinib and nivolumab was …

Introduction Brentuximab vedotin and PD-1 inhibitors have improved outcomes for classic
Hodgkin lymphoma (cHL), but better therapies are needed for patients who relapse after …

The treatment landscape of classical Hodgkin lymphoma has changed dramatically over the
past decade. Relapsed and refractory mainstay therapeutics such as brentuximab vedotin …

Introduction Brentuximab vedotin (BV) is an antibody-drug conjugate that delivers
monomethyl auristatin E (MMAE) to CD30+ cells and is safe and effective in …

Cílem této bakalářské práce je shrnout informace o inhibitorech Brutonovy tyrozinkinázy.
Dále práce obsahuje stručné informace o Brutonově tyrozinkináze a B buňkách. Zaměřuje …